Targeted imaging of tumor-associated M2 macrophages using a macromolecular contrast agent PG-Gd-NIR813
Source abstract
Abstract
Tumor-associated macrophages (TAMs) are diverse population containing multiple subtypes. M2 macrophages promote tumor growth and metastasis, in part by secreting a wide range of proangiogenic factors and growth factors. Selective depletion of M2 macrophages has been evaluated as a novel approach to anti-cancer therapy. In this study, a dual magneto-optical imaging probe, PG-Gd-NIR813 was synthesized and evaluated for non-invasive assessment of TAMs after intravenous injection. PG-Gd-NIR813 injected in nude rats bearing C6 tumors showed high uptake of the polymeric contrast agent in the tumor at 1 and 48 h after injection both in vivo and ex vivo optical imaging. T(1)-weighted MR imaging results showed accumulation of PG-Gd-NIR813 into the tumor necrotic area, which was confirmed by TUNEL staining of resected tumors. The uptake of PG-Gd-NIR813 within tumor necrosis decreased after animals were treated by the macrophage-depleting agent. Immunohistochemical staining demonstrated that PG-Gd-NIR813 colocalized with CD68 (marker for macrophages) and CD169 (marker for activated macrophages), but not with CD163 (residential macrophages). Using combined near-infrared fluorescence imaging and magnetic resonance imaging (MRI), we demonstrated that the accumulation of PG-Gd-NIR813 in tumors was mediated through M2 TAMs. Therefore, poly(L-glutamic acid) based reagents could be potentially used to image response to antitumor therapies targeted at M2 TAMs. Furthermore, poly(L-glutamic acid) is a promising carrier for candidate immunotherapeutics targeting M2 TAMs.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Immune cells in cancer · Nanoplatforms for cancer theranostics · Cancer, Hypoxia, and Metabolism
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (19)
Show source-provided references
1. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis10.1016/j.cell.2006.01.007 ↗
2. Tumour-educated macrophages promote tumour progression and metastasis10.1038/nrc1256 ↗
3. Alternative activation of macrophages10.1038/nri978 ↗
4. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies10.1002/path.1027 ↗
5. Tumor infiltrating macrophages reduce development of peritoneal colorectal carcinoma metastases10.1016/j.canlet.2007.11.040 ↗
6. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer10.1158/1078-0432.CCR-06-2073 ↗
7. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer10.1038/nm1609 ↗
8. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy10.1016/j.ejca.2006.01.003 ↗
9. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production10.1158/0008-5472.CAN-04-4037 ↗
10. Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents10.1093/jnci/90.21.1648 ↗
11. Behavior of endogenous tumor-associated macrophages assessed in vivo using a functionalized nanoparticle10.1593/neo.09356 ↗
12. Synthesis and characterization of poly(l-glutamic acid) gadolinium chelate: a new biodegradable MRI contrast agent10.1021/bc049910m ↗
13. Development of a macromolecular dual-modality MR-optical imaging for sentinel lymph node mapping10.1097/RLI.0b013e31804f5a79 ↗
14. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications10.1016/0022-1759(94)90012-4 ↗
15. Magnetic resonance imaging of therapy-induced necrosis using gadolinium-chelated polyglutamic acids10.1016/j.ijrobp.2007.01.011 ↗
16. Apoptosis in rat prostatic adenocarcinoma is associated with rapid infiltration of cytotoxic T-cells and activated macrophages10.1002/(SICI)1097-0215(19970502)71:3<451::AID-IJC24>3.0.CO;2-H ↗
17. Complete regression of well-established tumors using a novel water-soluble poly(l-glutamic acid)-paclitaxel conjugate
18. Antitumor activity of poly(l-glutamic acid)-paclitaxel on syngeneic and xenografted tumors
19. Potentiation of ovarian OCa-1 tumor radioresponse by poly (l-glutamic acid)-paclitaxel conjugate10.1016/S0360-3016(00)00757-4 ↗